Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
For the three months ended December 31, 2021 (Enanta’s fiscal first quarter of 2022). Enanta is a biotechnology company funding its wholly owned research and development programs primarily with royalties from AbbVie’s MAVYRET/MAVIRET hepatitis C regimens and existing financial resources. Its development focus includes RSV, HBV, SARS-CoV-2 and human metapneumovirus.
Key financial metrics
Amounts below are in millions of dollars, except per-share data and ratios.
| Metric | Q1 FY2022 | Prior-year quarter / comparison |
|---|---|---|
| Royalty revenue | $27.6 | $31.7; down 12.9% |
| Research and development expense | $48.5 | $36.7; up 32.4% |
| General and administrative expense | $9.5 | $7.4; up 28.9% |
| Operating loss | $(30.4) | $(12.3) |
| Net loss / diluted loss per share | $(30.1) / $(1.48) | $(8.3) / $(0.41) |
| Net cash used in operating activities | $(13.3) | $(14.9) |
| Cash, cash equivalents and marketable securities | $347.7 | $352.4 at September 30, 2021 |
Operating margin was approximately negative 110% of royalty revenue; gross margin is not presented because revenue is royalty-based. Current assets were $327.0 million and current liabilities $37.9 million at quarter-end. The balance sheet reports no borrowings; operating lease liabilities totaled $19.4 million, including current liabilities. Cash, cash equivalents and restricted cash rose $41.9 million during the quarter, largely reflecting marketable-security maturities and sales and $10.4 million of stock-option exercise proceeds. Operating cash use included an $8.5 million federal tax refund.
Material changes versus the prior comparable period
- Royalty revenue declined $4.1 million as AbbVie reported lower HCV sales, which Enanta linked to lower patient volumes and the continuing effects of COVID-19.
- R&D expense increased $11.9 million, primarily due to timing of manufacturing for virology clinical studies; lower liver-disease clinical-trial costs partly offset the increase. Virology R&D rose to $42.5 million from $24.6 million, while liver-disease R&D fell to $5.6 million from $11.2 million.
- Net loss widened by $21.8 million. The prior-year quarter included a $3.3 million tax benefit, versus a benefit of less than $0.1 million in the current quarter.
- Enanta extended its Watertown office and laboratory lease through September 1, 2027. Remeasurement increased the right-of-use asset and lease liability by $15.1 million; remaining minimum lease payments were $20.3 million.
Outlook, management commentary and risks
- Management said current financial resources and continuing royalties should fund operations for at least two years. It expects higher R&D expense in fiscal 2022 than in fiscal 2021 and anticipates continued net losses absent a significant increase in AbbVie sales or other revenue.
- Enanta expected topline RSVP study data for EDP-938 in the second quarter of calendar 2022, a Phase 1 study of EDP-235 to begin in February 2022, and a Phase 1 study of EDP-323 to begin in the second half of calendar 2022. These are forward-looking expectations, not reported outcomes.
- COVID-19 and its variants may continue to affect HCV treatment volumes, royalty revenue, RSV incidence and trial enrollment. Enanta said contract manufacturers were operating near normal levels but noted that supply, recruitment and trial timelines remain uncertain.
- Revenue concentration is material: substantially all royalty revenue derives from AbbVie’s HCV regimen, whose sales, pricing, reimbursement and market share Enanta does not control. The filing also highlights clinical-development, regulatory, competition, manufacturing, intellectual-property and financing risks.
- Enanta said it would discontinue further development of its NASH FXR agonists and pursue an out-license strategy. It reported no current litigation. It recorded a $28.8 million income-tax receivable related to an estimated fiscal 2021 federal net-operating-loss carryback refund.
- No numerical revenue or earnings guidance was provided. Management cautioned that quarterly results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Subsequent AbbVie HCV sales, patient volumes and Enanta’s royalty revenue, including any effects of annual royalty-tier resets.
- Whether stated clinical milestones were achieved and what trial data show, particularly for EDP-938, EDP-235 and EDP-323.
- Actual R&D spending, cash burn and liquidity relative to management’s estimate of at least two years of funding.
- Receipt and timing of the $28.8 million tax refund, and any changes to the tax receivable.
- Lease-related cash commitments and any further impacts of COVID-19 on trials, suppliers or royalty revenue.